These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 35158426)

  • 1. Quantifying the relationship between disability progression and quality of life in patients treated for NMOSD: Insights from the SAkura studies.
    Levy M; Haycox AR; Becker U; Costantino C; Damonte E; Klingelschmitt G; von Büdingen HC; Wallenstein G; Maio DD; Szczechowski L
    Mult Scler Relat Disord; 2022 Jan; 57():103332. PubMed ID: 35158426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term Efficacy of Satralizumab in AQP4-IgG-Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar.
    Kleiter I; Traboulsee A; Palace J; Yamamura T; Fujihara K; Saiz A; Javed A; Mayes D; Büdingen HV; Klingelschmitt G; Stokmaier D; Bennett JL
    Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36724181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar.
    Yamamura T; Weinshenker B; Yeaman MR; De Seze J; Patti F; Lobo P; von Büdingen HC; Kou X; Weber K; Greenberg B
    Mult Scler Relat Disord; 2022 Oct; 66():104025. PubMed ID: 36007339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of life of patients with multiple sclerosis and neuromyelitis optica spectrum disorders: Cross-sectional and longitudinal analysis.
    Kim S; Lee EJ; Kim KW; Seo D; Moon S; Kim KK; Lim YM
    Mult Scler Relat Disord; 2022 Feb; 58():103500. PubMed ID: 35032884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health utilities and costs for neuromyelitis optica spectrum disorder.
    Hughes DA; Bourke S; Jones A; Bhatt R; Huda S; Mutch K; Jacob A
    Orphanet J Rare Dis; 2022 Apr; 17(1):159. PubMed ID: 35392962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SAkuraBONSAI: Protocol design of a novel, prospective study to explore clinical, imaging, and biomarker outcomes in patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder receiving open-label satralizumab.
    Bennett JL; Fujihara K; Kim HJ; Marignier R; O'Connor KC; Sergott RC; Traboulsee A; Wiendl H; Wuerfel J; Zamvil SS; Anania VG; Buffels R; Künzel T; Lekkerkerker AN; Lennon-Chrimes S; Pittock SJ
    Front Neurol; 2023; 14():1114667. PubMed ID: 36873431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.
    Traboulsee A; Greenberg BM; Bennett JL; Szczechowski L; Fox E; Shkrobot S; Yamamura T; Terada Y; Kawata Y; Wright P; Gianella-Borradori A; Garren H; Weinshenker BG
    Lancet Neurol; 2020 May; 19(5):402-412. PubMed ID: 32333898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of psychiatric distress and physical disability on quality of life in neuromyelitis optica spectrum disorder and chronic autoimmune demyelinating polyneuropathies.
    Yalachkov Y; Soydaş D; Uhlmann V; Behrens M; Frisch S; Foerch C; Gehrig J
    Mult Scler Relat Disord; 2021 Feb; 48():102711. PubMed ID: 33383364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health utilities of patients with multiple sclerosis and neuromyelitis optica spectrum disorders in Thailand.
    Siritho S; Thavorncharoensap M; Chanatittarat C; Pasogpakdee P; Apiwattanakul M; Prayoonwiwat N; Chankrachang S; Riewpaiboon A; Chaikledkaew U
    Mult Scler Relat Disord; 2018 Aug; 24():151-156. PubMed ID: 30015079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world management of patients with neuromyelitis optica spectrum disorder using satralizumab: Results from a Japanese claims database.
    Nakashima I; Nakahara J; Yasunaga H; Yamashita M; Nishijima N; Satomura A; Nio M; Fujihara K
    Mult Scler Relat Disord; 2024 Apr; 84():105502. PubMed ID: 38401202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring steroid tapering in patients with neuromyelitis optica spectrum disorder treated with satralizumab in SAkuraSky: A case series.
    Yamamura T; Araki M; Fujihara K; Okuno T; Misu T; Guo YC; Hemingway C; Matsushima J; Sugaya N; Yamashita M; von Büdingen HC; Miyamoto K
    Mult Scler Relat Disord; 2022 May; 61():103772. PubMed ID: 35537314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early Initiation of Tocilizumab Treatment Against Moderate-to-Severe Myelitis in Neuromyelitis Optica Spectrum Disorder.
    Du C; Zeng P; Han JR; Zhang TX; Jia D; Shi FD; Zhang C
    Front Immunol; 2021; 12():660230. PubMed ID: 34745082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The mediating effect of health-related hardiness on the degree of physical disability and perceived stress in Chinese female patients with neuromyelitis optica spectrum disorder.
    Xu Y; Su X; Lu X; Zhang M; Wang W; Ding D; Chao Q; Jiang H
    Mult Scler Relat Disord; 2019 Oct; 35():67-72. PubMed ID: 31351263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dysphagia in neuromyelitis optica spectrum disorder and multiple sclerosis: A comparison of frequency, severity, and effects on quality of life.
    Afsharzadeh M; Mirmosayyeb O; Vaheb S; Shaygannejad A; Maracy M; Shaygannejad V
    Mult Scler Relat Disord; 2024 Jul; 87():105640. PubMed ID: 38692153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of treatments in Neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature.
    Velasco M; Zarco LA; Agudelo-Arrieta M; Torres-Camacho I; Garcia-Cifuentes E; Muñoz O
    Mult Scler Relat Disord; 2021 May; 50():102869. PubMed ID: 33711580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Disease: CHANCE
    Hümmert MW; Schöppe LM; Bellmann-Strobl J; Siebert N; Paul F; Duchow A; Pellkofer H; Kümpfel T; Havla J; Jarius S; Wildemann B; Berthele A; Bergh FT; Pawlitzki M; Klotz L; Kleiter I; Stangel M; Gingele S; Weber MS; Faiss JH; Pul R; Walter A; Zettl UK; Senel M; Stellmann JP; Häußler V; Hellwig K; Ayzenberg I; Aktas O; Ringelstein M; Schreiber-Katz O; Trebst C;
    Neurology; 2022 Mar; 98(11):e1184-e1196. PubMed ID: 35082170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
    Ma J; Yu H; Wang H; Zhang X; Feng K
    J Neuroimmunol; 2022 Feb; 363():577790. PubMed ID: 34959021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of Patients with Neuromyelitis Optica Spectrum Disorder Using the EQ-5D.
    Mealy MA; Boscoe A; Caro J; Levy M
    Int J MS Care; 2019; 21(3):129-134. PubMed ID: 31191178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder.
    Marignier R; Bennett JL; Kim HJ; Weinshenker BG; Pittock SJ; Wingerchuk D; Fujihara K; Paul F; Cutter GR; Green AJ; Aktas O; Hartung HP; Lublin FD; Williams IM; Drappa J; She D; Cimbora D; Rees W; Smith M; Ratchford JN; Katz E; Cree BAC;
    Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33771837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder.
    Yamamura T; Kleiter I; Fujihara K; Palace J; Greenberg B; Zakrzewska-Pniewska B; Patti F; Tsai CP; Saiz A; Yamazaki H; Kawata Y; Wright P; De Seze J
    N Engl J Med; 2019 Nov; 381(22):2114-2124. PubMed ID: 31774956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.